You are here: Industry Insights > Immuno-Oncology

News List

Takeda forms new alliances to boosts immuno-oncology portfolio pharmaceutical-technology
January 07, 2019
Takeda Pharmaceutical has formed new research alliances to bolster the discovery of next-generation immunotherapies, including cell therapy techniques, for the treatment of cancer......
Gilead and Agenus sign cancer drug development deal pharmaceutical-technology
January 03, 2019
Gilead Sciences has partnered with US-based biotechnology company Agenus for the development and commercialisation of up to five immuno-oncology (I-O) treatments.
Junshi Biosciences aims for $414M Hong Kong, S.A.R., China IPO: Reuters fiercebiotech
December 28, 2018
China’s Junshi Biosciences may follow in compatriot Innovent Biologics’ footsteps as it tees up to raise $414 million in its Hong Kong, S.A.R., China IPO....
As immuno-oncology heads into 2019, one thing is clear: It’s good to be Merck fiercepharma
December 24, 2018
When 2018 began, there was still plenty of uncertainty surrounding the previously untreated lung cancer market—the holy grail for immuno-oncology drugmakers, thanks to its sheer size.
Merck's Keytruda puts heat on Pfizer, Merck KGaA's Bavencio with new Merkel cell OK pharmatimes
December 24, 2018
Merck’s latest Keytruda approval isn’t necessarily a huge one for the New Jersey drugmaker when it comes to sales. But it’s a big deal for Pfizer and Merck KGaA, maker of rival drug Bavencio.
Gilead and Agenus sign cancer drug development deal pharmaceutical-technology
December 24, 2018
Gilead Sciences has partnered with US-based biotechnology company Agenus for the development and commercialisation of up to five immuno-oncology (I-O) treatments......
Gilead, Agenus Enter Immuno-Oncology Pact contractpharma
December 21, 2018
Gilead Sciences and Agenus Inc. have entered into an immuno-oncology (I-O) partnership for the development and commercialization of up to five novel immuno-oncology therapies.
Merck KGaA, Intrexon Amend CAR-T Alliance contractpharma
December 21, 2018
Merck KGaA, Darmstadt, Germany, through its wholly owned subsidiary, Ares Trading, amended its agreement with Intrexon Corp.
Bristol-Myers Squibb and Boston Medical Center announce research collaboration to investigate markers of immuno-oncology response and resistance worldpharmanews
December 18, 2018
Bristol-Myers Squibb Company and Boston Medical Center announced a multi-year joint research study to identify and analyze potential sensitivity and resistance markers in patients treated with standard-of-care checkpoint inhibitors.
Oxforb BioTherapeutics expands its strategic collaboration with WuXi Biologics pharmafocusasia
December 12, 2018
WuXi Biologics (2269.HK), a leading global open source biological technology platform company offering integrated solutions for discovery, development and biological ....

Previous page 1 2 3 4 5 6 7 8 9 10 Next page